Lysoway Therapeutics

📍 Cambridge, United States🗓 Founded 2020👥 7 employees💰 Last funded Jan 2024
Biotechnology Research🌐 lysoway.com
Website LinkedIn
Lysoway Therapeutics has developed unique technological approaches to screen and develop potent modulators of lysosomal ion channels, including TRPML1 and TMEM175. These small-molecule compounds can restore autophagic flux and resolution, as well as enhance plasma membrane repair through direct activation of lysosomal exocytosis. These modulators have great potential to treat neurodegenerative diseases with age-related decline of autophagy/lysosomal function or rare diseases characterized by toxic accumulation of cellular wastes.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
China
1
Frequently asked questions
Who invested in Lysoway Therapeutics?
Lysoway Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Lysoway Therapeutics last raise funding?
The most recent investment in Lysoway Therapeutics recorded on gritt.io was in January 2024.
When was Lysoway Therapeutics founded?
Lysoway Therapeutics was founded in 2020.
What industry is Lysoway Therapeutics in?
Lysoway Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Lysoway Therapeutics based?
Lysoway Therapeutics is headquartered in Cambridge, United States.